NCT06630806 - A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

November 13, 2028

Study Completion Date

May 14, 2029

Conditions

Plasma Cell Myeloma Refractory

Interventions

DRUG

SAR446523

Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)

Trial Locations (13)

2500

RECRUITING

Investigational Site Number : 0360001, Wollongong

3065

RECRUITING

Investigational Site Number : 0360002, Fitzroy

19107

RECRUITING

Thomas Jefferson University Hospital- Site Number : 8400002, Philadelphia

20089

RECRUITING

Investigational Site Number : 3800001, Rozzano (MI)

28040

RECRUITING

Investigational Site Number : 7240001, Madrid

60126

RECRUITING

Investigational Site Number : 3800002, Ancona

91120

RECRUITING

Investigational Site Number : 3760002, Jerusalem

3109601

RECRUITING

Investigational Site Number : 3760004, Haifa

6423906

RECRUITING

Investigational Site Number : 3760001, Tel Aviv

07601

RECRUITING

Hackensack Meridian School of Medicine- Site Number : 8400001, Hackensack

H4A 3J1

RECRUITING

Investigational Site Number : 1240001, Montreal

J1H 5N4

RECRUITING

Investigational Site Number : 1240002, Sherbrooke

08035

RECRUITING

Investigational Site Number : 7240002, Barcelona